ReviewFEBS letters2005
The therapeutic potential of RNA interference.
Review in FEBS letters, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 159 citations in OpenAlex.
- Aurora kinases signaling in cancer: from molecular perception to targeted therapies.Molecular cancer · 2025Review
- siRNA Treatments for Diabetic Neuropathy: Obstacles and Delivery Techniques.Current molecular medicine · 2025Review
- Multiplexed shRNA-miRs as a candidate for anti HIV-1 therapy: strategies, challenges, and future potential.Journal, genetic engineering & biotechnology · 2022Review
- Review
- Ubiquitin-Conjugating Enzymes in Cancer.Cells · 2021Review
- Nucleic acid-based therapy for coronavirus disease 2019.Heliyon · 2020Review
- Article
- Nanoparticles Targeting STATs in Cancer Therapy.Cells · 2019Review
- miRNAs in Tuberculosis: New Avenues for Diagnosis and Host-Directed Therapy.Frontiers in microbiology · 2018Review
- Dendrimer- and copolymer-based nanoparticles for magnetic resonance cancer theranostics.Theranostics · 2018Review
- RNAi technique, how far is it from pediatrics?Pediatric investigation · 2017Article
- Therapeutic effects of protein kinase N3 small interfering RNA and doxorubicin combination therapy on liver and lung metastases.Oncology letters · 2017Article
- A multi-shRNA vector enhances the silencing efficiency of exogenous and endogenous genes in human cells.Oncology letters · 2017Article
- RNA interference in head and neck oncology.Oncology letters · 2016Article
- Targeting blockage of STAT3 inhibits hepatitis B virus-related hepatocellular carcinoma.Cancer biology & therapy · 2016Review
- Inhibition of pulmonary cancer progression by epidermal growth factor receptor-targeted transfection with Bcl-2 and survivin siRNAs.Cancer gene therapy · 2015Article
- Review
- EMMPRIN reduction via scFv-M6-1B9 intrabody affects α3β1-integrin and MCT1 functions and results in suppression of progressive phenotype in the colorectal cancer cell line Caco-2.Cancer gene therapy · 2014Article
- FOXM1 and its oncogenic signaling in pancreatic cancer pathogenesis.Biochimica et biophysica acta · 2014Article
- Diseases originate and terminate by genes: unraveling nonviral gene delivery.Drug delivery and translational research · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, we have witnessed the discovery of a new mechanism of gene regulation called RNA interference (RNAi), which has revitalized interest in the development of nucleic acid-based technologies for therapeutic gene suppression. This review focuses on the potential therapeutic use of RNAi, discussing the theoretical advantages of RNAi-based therapeutics over previous technologies as well as the challenges involved in developing RNAi for clinical use. Also reviewed, are the in vivo proof-of principle experiments that provide the preclinical justification for the continued development of RNAi-based therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.